Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19911693 | 1.00 | IDO1 (0.47) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL19911670 | 0.84 | IDO1 (0.47) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL19911671 | 0.84 | IDO1 (0.47) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL28268551 | 0.84 | IDO1 (0.47) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL9373544 | 0.84 | IDO1 (0.44) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL19911672 | 0.84 | IDO1 (0.44) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL19911668 | 0.84 | IDO1 (0.44) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL9373549 | 0.84 | IDO1 (0.44) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL9378221 | 0.83 | IDO1 (0.42) | IDO1CHRM2CHRM1CHRM3PIN1 | |
| SCHEMBL9378215 | 0.83 | IDO1 (0.42) | IDO1CHRM2CHRM1CHRM3PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | claimed |
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-11168052-B2 | Carbamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. | 2021-11-09 | — | — | US | disclosed |
| US-20180057449-A1 | CARBAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-03-01 | — | — | US | disclosed |
| US-20180057449-A1 | CARBAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168052-B2 | Carbamate derivative compounds, processes for preparing them and their uses | ACHE, BCHE, AQP4 | IDO1 2586/4885CHRM2 120/4885CHRM1 236/4885 |
| US-20180057449-A1 | CARBAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | ACHE, BCHE, AQP4 | IDO1 2586/4885CHRM2 120/4885CHRM1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.